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Abstract
Background: Blood coagulation plays a crucial role in the blastocyst implantation process and its alteration may be
related to in vitro fertilization (IVF) failure. We conducted a prospective observational longitudinal study in women
eligible for IVF to explore the association between alterations of coagulation with the IVF outcome and to identify the
biomarkers of hypercoagulability which are related with this outcome.
Methods: Thirty-eight women eligible for IVF (IVF-group) and 30 healthy, age-matched women (control group)
were included. In the IVF-group, blood was collected at baseline, 5–8 days after administration of
gonadotropin-releasing hormone agonist (GnRH), before and two weeks after administration of human
follicular stimulating hormone (FSH). Pregnancy was monitored by measurement of βHCG performed 15 days
after embryo transfer. Thrombin generation (TG), minimal tissue factor-triggered whole blood
thromboelastometry (ROTEM®), procoagulant phospholipid clotting time (Procoag-PPL®), thrombomodulin
(TMa), tissue factor activity (TFa), factor VIII (FVIII), factor von Willebrand (FvW), D-Dimers and fibrinogen were
assessed at each time point.
Results: Positive IVF occurred in 15 women (40%). At baseline, the IVF-group showed significantly increased TG, TFa and
TMa and significantly shorter Procoag-PPL versus the control group. After initiation of hormone treatment TG was
significantly higher in the IVF-positive as compared to the IVF-negative group. At all studied points, the Procoag-PPL was
significantly shorter and the levels of TFa were significantly higher in the IVF-negative group compared to the IVF-positive
one. The D-Dimers were higher in the IVF negative as compared to IVF positive group. Multivariate analysis retained the
Procoag-PPL and TG as predictors for the IVF outcome.
Conclusions: Diagnosis of women with hypercoagulability and their stratification to risk of IVF failure using a model
based on the Procoag-PPL and TG is a feasible strategy for the optimization of IVF efficiency that needs to be validated in
prospective trials.
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Background
The link between blood hypercoagulability and infertility
or in vitro fertilization (IVF) failure is a puzzling issue. Hy-
percoagulability could be intrinsic or caused by the hor-
mone treatment preceding the IVF procedure [1–6].
Tissue factor is the major trigger of blood coagulation and
thrombin generation is the ultimate step that leads to fi-
brin formation. The activation of coagulation induced by
tissue factor (TF) expressed by perivascular decidualized
human endometrial stromal cells is an essential part of the
mechanism that favors blastocyst implantation and pre-
vents peri-implantational hemorrhage during endovascu-
lar trophoblast invasion. Thrombin generation is required
for cell proliferation, neoangiogenesis, trophoblast inva-
sion and remodeling of the spiral arteries and arterioles
[7–9]. Thus, the shift of blood coagulation equilibrium to-
wards locally enhancement of thrombin generation may
have some beneficial effects for a positive outcome of IVF.
On the other hand, in infertile women activation or dys-
function of platelets, endothelial cells and monocytes has
been observed [10, 11].
Newer laboratory assays allow the assessment of global
blood coagulation and clot formation process. Among
them, the Calibrated Automated Thrombogram® and the
minimal TF-triggered whole blood thromboelastometry
allow the evaluation of thrombin generation and clot
formation processes [12–14]. The measurement of the
procoagulant phospholipid dependent clotting time
(Procoag-PPL®) reflects the plasma concentration of pro-
coagulant membrane vesicles of cellular origin [15, 16].
Biomarkers of endothelial cell activation such as throm-
bomodulin activity (TMa) and TF activity (TFa) mea-
sured in plasma offer information on the status of the
endothelial cells at the vasculature.
The aim of the present prospective, observational longi-
tudinal study was to identify biomarkers of hypercoagula-
bility which could have some predictive value for the IVF
outcome. Thrombin generation, clot formation kinetics
and molecular biomarkers of cellular hypercoagulability
were assessed at women eligible for IVF at baseline (before
any hormone treatment administration), at the down-
regulation phase of the menstrual cycle and after ovarian
stimulation. Biochemical diagnosis of pregnancy was the
end-point of the study.
Methods
Study design and participants
A monocentric prospective, non-interventional cohort
study was designed. From June 2014 to June 2015 blood
samples were obtained from 38 women eligible for IVF
(IVF-group). Women were recruited at the baseline con-
sultation and then they were followed until pregnancy
test was performed. Biochemical diagnosis of pregnancy
was the end-point of the study. According to the levels of
β-chorionic gonadotropin (βHCG) women were stratified
into two subgroups: IVF-positive if βHCG levels were
higher than 100 IU/L and IVF-negative if (βHCG) levels
were equal or lower than 100 IU/L. The evolution of the
pregnancy was not recorded.
The control group consisted of 30 healthy, age-matched
women, without any known hereditary or acquired throm-
bophilic alteration or personal history of thrombotic or
bleeding disorder who had undergone at least one un-
eventful physically conceived pregnancy and without any
personal history of miscarriage. The protocol of the study
was in accordance with the commitment of the Helsinki
declaration and was approved by the institutional ethics
committee. All subjects provided informed written con-
sent before inclusion in the study.
Inclusion criteria
Women were eligible for IVF according to established
selection criteria applied in our institution. All women
had full blood count, platelet count, prothrombin time,
activated partial thromboplastin time, fibrinogen, renal
and liver function within the normal range.
Exclusion criteria
Women younger than 18 years or older than 45 years,
weight less than 50 kg or more than 100 kg, with a personal
or family history of venous thromboembolism (VTE) or
hemorrhagic syndromes, known hereditary or acquired
thrombophilia, active anticoagulant or antiplatelet treat-
ment or use of these agents during the last 30 days before
inclusion, hospitalization for any reason within the previous
3 months, abnormal full blood count or platelet count and
ongoing cardiovascular, renal or liver disease, malignancy,
or arterial hypertension, known systematic or chronic dis-
ease (autoimmune syndrome, heart disease, severe or un-
controlled thyroid disease or HIV infection), treatment
with non-steroid anti-inflammatory drugs within the last
10 days before inclusion, ovarian insufficiency (FSH > 9 IU/
ml and/or number of antral follicles <8) or polycystic ovary
syndrome (defined according to the Rotterdam criteria).
Hormone treatment for the artificial reproductive
technique
Estrogen production was first down-regulated to induce
controlled ovarian stimulation. Three different protocols
of down regulation were used: a long gonadotropin-
releasing hormone (GnRH) agonist or a short agonist or
an antagonist. Ovarian stimulation was done with re-
combinant human follicular stimulating hormone (FSH)
at doses ranging from 75 IU to 450 IU per day depend-
ing on age, body mass index (BMI), antral follicle count,
size and number of follicles and estradiol levels (E2). This
stimulation was initiated once pituitary desensitization
had been achieved (E2 level <50 pg/mL). The response
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was followed by E2 measurement six days later and by
ultrasound scanning of the ovarian follicles at days 9–10
after the first FSH injection, and repeated when necessary.
Transvaginal oocyte retrieval was scheduled 35 to 36 h
after human recombinant chorion gonadotrophin (hCG)
injection and embryo transfer was performed 2–3 days
later. On day 2, individually cultured embryos were
evaluated on the basis of the number of blastomeres,
blastomere size, fragmentation rate and presence of
multinucleated blastomeres. Therefore, the ovocytes
were retrieved 10 to 14 days after starting the stimulation
with the FSH.
Outcomes
Achievement of biochemical pregnancy was the outcome
of the study. Pregnancy was controlled by quantitative
measurement of βHCG 15 days after embryo transfer.
Blood sampling
Blood samples were collected before the administration of
any hormone treatment (T0) and during the IVF procedure
as follows: at the maximal down-regulation of the men-
strual cycle; between the 5th and 8th day from the adminis-
tration of the GnRH agonist (T1); at maximal stimulation
after treatment by FSH and before hCG injection (T2) and
two weeks after gonadotropin-releasing hormone (GnRH)
injection (T3). Blood samples were obtained by atraumatic
puncture of the antecubital vein, using a 20-gauge needle
without tourniquet, into siliconized vacutainer tubes con-
taining 0.105 mol/L trisodium citrate; 1/9 v/v (Becton and
Dickinson, France). Platelet-poor plasma (PPP) was ob-
tained by double centrifugation at 2000 g for 20 min at
room temperature and plasma aliquots were stored at
−80 °C until assayed. Samples were assessed within two
weeks after collection. Thromboelastometry was carried
out with fresh whole blood.
Molecular and functional analysis
Thrombin generation assay. Thrombin generation in
plasma was assessed using the Calibrated Automated
Thrombogram assay (CAT®, Diagnostica Stago, Asnières
France) according to manufacturers’ instructions, in the
presence of optimal concentrations of TF (5 pM) and
procoagulant phospholipids (4 μM) using the PPP-
Reagent®. Assay’s performance has been published else-
where [12, 17].
Minimal TF-triggered whole blood thromboelasto-
metry (min TF-WB TEM) was assessed in citrated whole
blood, on the ROTEM® instrument (TEM®, Munich,
Germany). Thromboelastometry was performed at 37 °C in
citrated fresh whole blood within 30 min after veinipunc-
ture using 5 pM of TF as described elsewhere [18]. The fol-
lowing parameters of the thromboelastometric trace were
analyzed: (a) Clotting time (CT, in sec): time from the start
of the sample run to the point of first significant clot ap-
pearance corresponding to an amplitude of 2 mm, (b) Clot
formation time (CFT, in sec): time from CT until the level
of clot firmness reaches an arbitrary value of 20 mm, (c) α-
angle (degree): measurement of clot development kinetics,
(d) Maximum clot firmness (MCF in mm): the maximum
vertical amplitude of the thromboelastogram.
Procoagulant phospholipid-dependent clotting time
(Proag-PPL) was measured with STA®Procoag-PPL,
(Diagnostica Stago, Asnières, France) according to the
manufacturer’s instructions as described elsewhere. The
inter- and intra-assay coefficients of variation were 3 and
4% respectively.
Thrombomodulin activity. Plasma levels of thrombo-
modulin activity (TMa) were measured with a functional
test on the STA-R analyzer (Diagnostica Stago, Asnières,
France) as described elsewhere [19]. The inter- and intra-
assay coefficients of variation were 5 and 6% respectively.
Specific TF activity. Tissue Factor activity (TFa) in
PPP was measured with a clotting-based assay as previously
described [20, 21]. The inter- and intra-assay coefficients of
variation were 7% and 5% respectively. The levels of, FVIII,
FvW, D-Dimers and fibrinogen were measured with
conventional assays according to the manufacturer’s
instructions (Diagnostica Stago, Asnières, France).
Statistical analysis
The calculation of the sample size was based on the mini-
mum number of patients required for a significant power
for the detection of differences (a) between the IVF and
control group, (b) at the IVF at the studied time points,
(c) between IVF positive and IVF negative groups. The
minimum sample size of 27 individuals for each group
(IVF and control as well as IVF at each time point) was
defined to warrant a two-tail significance at the limit of
5% and a prediction power of 95% with a two-sided α level
of 0.05. Regarding the sub-group analysis (IVF positive
and IVF negative) the minimum size of 15 patients for
each group warrants two-tail significance at the limit of
5% and a prediction power of 85% with a two-sided α level
of 0.05.
Special effort and attention was given to avoid missing
values. The data are presented as mean ± sd. The Mann–
Whitney test for independent samples was used for the
comparisons of the studied parameters between the IVF
and the control group and between the IVF-positive and
IVF-negative group. Non-parametric Wilcoxon test for re-
lated samples and ANOVA test were applied to compare
changes in variables at the studied time points during the
observation period. Pearsons’ test was applied to control
correlation between thrombogram parameters and studied
blood coagulation variables. Dichotomous variables were
compared with χ2 test. The Upper Normal Limit (UNL)
and the Lower Normal Limit (LNL) for each parameter of
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the studied variables were defined in the control group as
follows: UNL=mean + 2 SD, and LNL: = mean – 2 SD.
The UNL and LNL of the studied biomarkers were defined
in the control group and were compared to the corre-
sponding normal reference range used by our laboratory.
The normal ranges have been established according to the
requirements for the good quality of laboratory practice by
performing the tests in healthy individuals representative
of the general population regarding age, sex, ethnicity,
BMI. Two-sided values of p < 0.05 were considered as sta-
tistically significant.
The model development started by defining the positive
diagnosis of pregnancy (if βHCG levels were equal or
lower than 100 IU/L) as the dependent variable. The first
step consisted of the univariate analysis in order to iden-
tify the variables associated with positive pregnancy. The
selection of independent variables (which are the bio-
markers of hypercoagulability) was done at the level of 5%
using the stepwise procedure. The multivariable linear re-
gression model was used to explore the effect of the inde-
pendent variables on pregnancy outcome. The variables,
found to be significant in the univariate analysis (p < 0.05)
were included in the multivariate analysis. The variable
with the highest p value was excluded from the model.
The discrimination capacity of the model was tested with
receiver operating characteristics (ROC) analysis and the
area under the curve (AUC) was calculated for the quanti-
fication of the discrimination capacity of the model. The
SPSS statistical software package (Chicago inc 6.1) was
used for statistical analysis. Values are mean ± standard
deviation.
Results
In total 38 women were eligible for the study and com-
pleted the follow up. The clinical and demographic char-
acteristics of the studied groups are shown in Table 1.
Positive IVF occurred in 15 women (40%) and negative
in 23 (60%). The demographic characteristics and the in-
dication for IVF were similar in the IVF-positive and
IVF-negative group. None of the women included in the
IVF and the control group had hypertension, hyperlipid-
emia or diabetes. None of the women suffered thrombo-
embolic complication.
The UNL and LNL of the studied biomarkers in the
control group were not significantly different as com-
pared to the respective normal reference ranges used in
our laboratory (Table 2).
Baseline profile
At T0, the IVF-group showed significantly increased
thrombin generation (marked by shorter lag-time and
ttPeak and higher ETP, Peak and MRI), and significantly
shorter Procoag-PPL as compared to the control group.
At least one thrombogram parameter was higher than
the UNL in 50% of women and lower than the LNL in
14%. The IVF group also had significantly higher levels
of TFa, TMa. The levels of FVIII, FvW, D-Dimers and fi-
brinogen were not significantly different between the
IVF-group and the control group (Table 2).
Effect of down-regulation of the menstrual cycle
At T1, thrombin generation, Procoag-PPL, TFa, TMa,
FVIII, fibrinogen and D-Dimers were not significantly
different as compared to T0. The levels of FvW signifi-
cantly increased as compared to T0 (Table 2). Women
with ETP, Peak or MRI above the UNL at T0 did not
show any significant differences at T1.
Effect of ovarian stimulation
At T2, Peak, MRI and the levels of FVIII and D-Dimers
were significantly increased as compared to T1 (Table 2).
In contrast the Procoag-PPL and the levels of TFa, TMa
and FvW did not vary significantly as compared to T1.
Effect of GnRH treatment
At T3, thrombin generation was not significantly differ-
ent as compared to T2. The Procoag-PPL, TFa and
TMa, FvW, and fibrinogen remained at the same levels
Table 1 Demographic and clinical characteristics of women











Age (years) 33.7 ± 3.5 33.7 ± 3.5 33.7 ± 3.5 32.2 ± 2.2
BMI 22.8 ± 2.9 22.8 ± 2.9 22.8 ± 2.9 23.8 ± 2.1
Indication for IVF
endometriosis 2 1 1 –




tubal 4 2 2 –
male origin 14 7 7 –
Previous pregnancy
0 31 15 16 –
1 4 3 1 10
2 3 1 2 20
Previous miscarriages
0 36 17 19 30




7 (18%) 3 (10%) 4 (13%) 8 (27%)
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as in T2. The levels of FVIII significantly decreased at
T3 as compare to T2. The levels of D-Dimers signifi-
cantly increased as compared to T2 (Table 2).
At all studied time points the parameters of thromboe-
lastometry were not significantly different between the
IVF-group and the control group (Table 2).
Blood hypercoagulability and IVF outcome
At T2 and T3 the ETP, Peak and MRI were significantly
higher in the IVF-positive as compared to the IVF-negative
group. At T0, T1 and T2 the Procoag-PPL was significantly
shorter in the IVF-negative group compared to the IVF-
positive group. At all time points except T3, the levels of
TFa were significantly higher in the IVF-negative group as
compared to the IVF-positive group. The levels of TMa
were significantly higher in the IVF-negative group as com-
pared to the IVF-positive group only at T2. At T2 and T3
FVIII levels were significantly lower in IVF negative as
compared to IVF positive. At T2 and T3, D-Dimers were
significantly higher in the IVF-negative as compared to the
IVF-positive group. At T1 and T2, the CT was significantly
shorter in the IVF-positive group as compared to the IVF-
negative. (Table 2).
The Procoag-PPL was inversely correlated with the lag-
time (r = −0.304; p = 0.013), ETP (r = −0,4; p = 0.001) and
MRI (r = −0.380; p = 0.002) as well as with the TFa (r =
−0.399; p = 0.001). Thrombomodulin was inversely corre-
lated with ETP (r = −0.346; p = 0.019).
Univariate analysis showed the following biomarkers
to have a significant correlation with the positive out-
come of IVF: at T0, the FvW; at T1 the ETP, Peak, MRI,
Procoag-PPL and TFa; at T2, the ETP, Peak, MRI,
Procoag-PPL, TFa and D-Dimers (Table 3).
There was a strong association between IVF-positive
outcome and Procoag-PPL longer than 31.1 sec. Women
who had Procoag-PPL between 31.1 and 54.9 sec had
24-fold higher probability for pregnancy than the women
with Procoag-PPL values lower than 31.1 sec.
Multivariate analysis for the identification of biomarkers
which are correlated with a positive outcome of IVF
retained the Procoag-PPL and MRI of thrombin gener-
ation. Multivariate analysis applied at the T1 led to the
construction of a prediction model including the Procoag-
PPL and the MRI according to the equation:
Y ¼ 0:043MRIð Þ 0:45Procoag‐PPLð Þ
The ROC curve showed a very good specificity and
sensitivity of the model for the prediction of pregnancy
since the area under the curve was 0.99 (Fig. 1).
Discussion
The present prospective longitudinal observational study
demonstrates that at baseline, women eligible for IVF
present blood hypercoagulability which is characterized by
significant increase of platelet and endothelial cell activation
biomarkers. The baseline state of cellular hypercoagulabil-
ity, which persisted practically unchanged during the period
of hormone treatment administration for IVF, was con-
sisted of significantly shortening of Procoag-PPL clotting
time. This test is correlated with increased concentration of
procoagulant microparticles derived from platelets or other
cells [22, 23]. The levels of TFa and TMa, at baseline and
during hormone treatment, were also significantly in-
creased as compared to age-matched women with naturally
occurring uneventful pregnancies. The TFa and TMa are
biomarkers of endothelial cell or platelet activation [24–26].
In addition, increased TFa levels in plasma is a marker of
monocyte activation [27]. The Procoag-PPL, TFa and TMa
levels were not significantly modified during treatment for
estrogen down-regulation and ovarian stimulation indicat-
ing that the shift towards cellular hypercoagulability ob-
served at baseline was not correlated with hormone
variations. The data from the present study are in accord-
ance with those recently published by Olausson et al. which
demonstrate that platelet, endothelial and monocyte-
derived microparticles and inflammation biomarkers are
significantly increased in women undergoing IVF [28].
Thrombin generation was also significantly enhanced but
the baseline levels of FVIII, FvW, D-Dimers and fibrinogen
were similar to those observed in the control group, con-
firming previous studies [4]. To the best of our knowledge,
this is the first study showing that infertility is linked to a
systemic cell activation that offers procoagulant substances,
mainly endothelial cells and platelets. This concept is sup-
ported by recent studies reporting that increased levels of
plasminogen activator inhibitor 1 (PAI-1), thrombin activa-
table fibrinolysis inhibitor (TAFI) or tissue factor pathway
inhibitor (TFPI), which are synthesized and secreted by ac-
tivated endothelial cells are related with infertility and IVF
failure [29–32].
Furthermore, the present study showed that short
Procoag-PPL clotting time as well as increased TFa and
TMa levels are independent risk factors for IVF failure.
The implication of high levels of TF and procoagulant
microparticles in the pathogenesis of infertility, IVF fail-
ure and vascular complications during pregnancy, such
as recurrent first trimester miscarriage, fetal loss, still-
birth, early and severe pre-eclampsia or prematurity has
already been reported by others (reviewed in [33, 34]).
Herein, we demonstrate for a first time that the short-
ened Procoag-PPL associated with the mean rate index
(MRI) of the propagation phase of thrombin generation
assessed at the maximal down-regulation of the men-
strual cycle (between the 5th and 8th day from the ad-
ministration of the GnRH agonist) are predictors of IVF
outcome. These tests could be used in the construction
of a risk assessment model for IVF issue. The design of
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the present study does not allow the identification of the
underlying causes that lead to cellular activation and hy-
percoagulability which is observed at baseline. This in-
vestigation appears to be attractive for the elucidation of
the link with hypercoagulability in women eligible for
IVF. The association between hypercoagulablity and
negative IVF outcome has recently been reported by Di
Nisio et al., who proposed that the increase of D-Dimers
levels in plasma is a predictor for IVF failure [35]. The
implication of increased D-Dimers in the sterility is fur-
ther supported by the data presented by Di Micco et al.
[36]. The univariate analysis of the data reported herein
confirms that the increase of D-Dimers during hormone
treatment is a negative prognostic factor for IVF out-
come. However, the impact of D-Dimers disappeared in
the multivariate analysis indicating that high concentra-
tions of procoagulant phospholipids, detected by the
short Procoag-PPL, have a dominant role in negative
IVF outcome.
Interestingly, increased thrombin generation was found
to be a positive predictor for IVF outcome. This finding is
in accordance with the concept that thrombin generation is
necessary for blastocyst implantation, remodeling of decid-
ualized human endometrial stromal cells and subsequent
trophoblast invasion and remodeling of the spiral arteries
and arterioles; a process driven by TF expression in the
endometrial microenvironment which is in contact with
mother’s blood [7–10]. The concept that the non-suffering
of endothelial cells, platelets or other cells that potentially
release procoagulant phospholipids, is determinant for a
positive IVF outcome is supported by our study. Indeed,
the presence of high levels of procoagulant phospholipids
Table 3 Univariate analysis and odds ratio of thrombin generation test and the biomarkers of hypercoagulability for the positive IVF
outcome






















































































































Fig. 1 The ROC analysis of the prediction model of the IVF outcome
based on the MRI and Procoag-PPL. The AUC is 0.9667
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in plasma, as expressed by shortened Procoag-PPL was the
dominant parameter related with IVF failure while the de-
crease of thrombin generation was found to be a comple-
mentary factor. Control measurements showed that factor
V and factor II levels were within the normal range (data
not shown) ruling out clotting factors’ consumption. The
reasons for which thrombin generation is decreased in
women with IVF failure have to be investigated.
At all studied time points the parameters of thromboe-
lastometry were not significantly different between the
IVF-group and the control group. Fibrinogen levels,
platelet count and hematocrit are variables with a major
impact on thromboelastometric profile. Both IVF-group
and the control group had these variables within the
normal ranges.
We found that when the ovarian stimulation was max-
imal, thrombin generation, FVIII, FvW and D-Dimers
levels were significantly increased, in agreement with older
studies [5, 37–41]. However, these changes were not
reflected on the kinetics of clot formation and its qualita-
tive characteristics when coagulation was triggered by a
low TF concentration. In women undergoing hormone
treatment for IVF preparation thromboelastographic ana-
lysis performed after triggering contact system showed a
slight but significant acceleration of the kinetics of clot
formation following GnRH treatment indicating that peak
concentrations of estrogens are associated with a pos-
sible enhancement of FXII activation [42]. Women
who had baseline thrombin generation above the UNL
remained at the same levels during the down-regulation
and the stimulation phase of the treatment (data not
shown). Therefore, our data, in agreement with previous
studies [43] and support the concept that hormone treat-
ment for IVF represents a mild procoagulant stimulus,
which has a minor effect on the global haemostatic bal-
ance, the kinetics of clot formation or its qualitative char-
acteristics. Two weeks after hCG injection and embryo
transfer, thrombin generation, TMa, TFa and Procoag-PPL
remained without any significant modifications as com-
pared to the phase of ovarian hyperstimulation. In con-
trast, the D-Dimers tended to increase and this finding
is in agreement with others [2]. De Nisio et al., found
that one week after the administration of gonadotropin,
D-Dimers levels increased considerably [35]. We also
found that even two weeks after GnRH injection
D-Dimers levels are still increased, reflecting enhanced
fibrin formation or fibrinolysis following r-hCG, as
described by Biron et al. [2].
The present study has some limitations. The number of
the enrolled women, although it provides sufficient statis-
tical power to identify the most relevant biomarkers related
with IVF outcome, does not allow generalizability of the
model. The group of IVF women was heterogeneous re-
garding the IVF indication. In some women the indication
of the IVF was of male origin. Although the elimination of
these cases did not significantly influence the final results,
this does not warrant that the presence of this subpopula-
tion had no impact on the results. A new prospective study
in a larger population is planned to corroborate these find-
ings. Women enrolled in the study were treated with three
different protocols for estrogen down-regulation. The sub-
group analysis according to the therapeutic protocol did
not demonstrate any significant difference on the studied
biomarkers among the subgroups (data not shown). Several
different hormone treatments and protocols are applied for
IVF preparation by the different IVF centers. Whether this
protocol variability influences the kinetics of the studied
biomarkers has to be investigated. However, the major find-
ings of our study, which are (a) the presence of cell derived
hypercoagulable state at the baseline, before any treatment
administration and (b) the predictive value of the Procoag-
PPL clotting time associated with the MRI of thrombin
generation on IVF outcome are not influenced by the sub-
sequent hormone treatments for ovarian stimulation. Al-
though this study fulfils the criteria for the statistical power
in the selection of the most clinically relevant biomarkers, a
new prospective independent validation of this model is re-
quired in a larger multicenter study.
It has been suggested that heparin may improve the
intrauterine environment in sub-fertile women, by enhan-
cing growth factors to improve attachment of the embryo
to the lining of the womb [44]. Thus low molecular weight
heparin (LMWH) is often offered to women eligible for
IVF as an adjunct treatment in an attempt to improve the
probability for a positive outcome. However, a recent meta-
analysis showed that it is unclear whether peri-implantation
heparin administration in assisted reproduction treatment
cycles improves clinical pregnancy rates in sub-fertile
women [45]. The elaboration of a risk assessment model
with the clinically relevant biomarkers of hypercoagulability
proposed by the present study is of clinical interest in order
to identify women who could benefit from the peri-
implantation administration of antithrombotic treatment.
Conclusions
The data presented herein show that hypercoagulability
of cellular origin is the dominant biological process
related with IVF failure. Hypercoagulabilty of cellular
origin appears at the baseline, before any hormone treat-
ment administration and it is not modified by this treat-
ment. The administration of hormone treatment during
the IVF preparation does not lead to substantial alter-
ation of global coagulation process. Among the large
variety of the studied biomarkers, the evaluation of both
Procoag-PPL and MRI of thrombin generation after
down-regulation of the menstrual cycle appear to be the
most clinically relevant biomarkers for the identification
of the women at risk of IVF failure.
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